Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
15 stories
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
Alnylam reported $1,292 million in quarterly net product revenue, expanded its nucresiran Phase 3 study to 2,250 patients, and reported Phase 1 data for brezosiran in Huntington's disease.
SEC filing (2)
Kiniksa lifted its 2026 ARCALYST revenue outlook to $1.045-$1.050 billion and said pivotal Phase 3 data on KPL-387 are still expected in the second half of 2027.
SEC filing (6)
Sanofi will pay Regeneron a $1.0 billion upfront fee and up to $7.0 billion in milestones under a sixth amendment to their antibody license deal, while the companies also settled a related lawsuit.
SEC filing
An 8-K filed September 30, 2026 details a 10-year performance award for CEO Leonard Schleifer and CSO George Yancopoulos and discloses equity stakes in a newly formed subsidiary.
SEC filing